129 related articles for article (PubMed ID: 8625775)
1. Changes in serum levels of metalloproteinases and their inhibitors by treatment of chronic hepatitis C with interferon.
Arai M; Niioka M; Maruyama K; Wada N; Fujimoto N; Nomiyama T; Tanaka S; Okazaki I
Dig Dis Sci; 1996 May; 41(5):995-1000. PubMed ID: 8625775
[TBL] [Abstract][Full Text] [Related]
2. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response.
Kasahara A; Hayashi N; Mochizuki K; Oshita M; Katayama K; Kato M; Masuzawa M; Yoshihara H; Naito M; Miyamoto T; Inoue A; Asai A; Hijioka T; Fusamoto H; Kamada T
J Hepatol; 1997 Mar; 26(3):574-83. PubMed ID: 9075665
[TBL] [Abstract][Full Text] [Related]
3. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases -1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis.
Walsh KM; Timms P; Campbell S; MacSween RN; Morris AJ
Dig Dis Sci; 1999 Mar; 44(3):624-30. PubMed ID: 10080160
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic potential of serum matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as non-invasive markers of hepatic fibrosis in patients with HCV related chronic liver disease.
El-Gindy I; El Rahman AT; El-Alim MA; Zaki SS
Egypt J Immunol; 2003; 10(1):27-35. PubMed ID: 15719620
[TBL] [Abstract][Full Text] [Related]
5. Significance of serum matrix metalloproteinases and their inhibitors on the antifibrogenetic effect of interferon-alfa in chronic hepatitis C patients.
Ninomiya T; Yoon S; Nagano H; Kumon Y; Seo Y; Kasuga M; Yano Y; Nakaji M; Hayashi Y
Intervirology; 2001; 44(4):227-31. PubMed ID: 11509885
[TBL] [Abstract][Full Text] [Related]
6. Histological changes of the liver by treatment of chronic non-A, non-B hepatitis with recombinant leukocyte interferon alpha. Comparison with histological changes in chronic hepatitis B.
Omata M; Ito Y; Yokosuka O; Imazeki F; Uchiumi K; Takano S; Hosoda K; Ohto M
Dig Dis Sci; 1989 Mar; 34(3):330-7. PubMed ID: 2493364
[TBL] [Abstract][Full Text] [Related]
7. Effect of lamivudine treatment on plasma levels of transforming growth factor beta1, tissue inhibitor of metalloproteinases-1 and metalloproteinase-1 in patients with chronic hepatitis B.
Flisiak R; Al-Kadasi H; Jaroszewicz J; Prokopowicz D; Flisiak I
World J Gastroenterol; 2004 Sep; 10(18):2661-5. PubMed ID: 15309715
[TBL] [Abstract][Full Text] [Related]
8. Interferon treatment of chronic active hepatitis C in patients with end-stage chronic renal failure.
Ozyilkan E; Simşek H; Uzunalimoğlu B; Telatar H
Nephron; 1995; 71(2):156-9. PubMed ID: 8569947
[TBL] [Abstract][Full Text] [Related]
9. Treatment of chronic hepatitis C infection with interferon alpha-2a in a Turkish population.
Simsek H; Tatar G; Savas C; Telatar H
J Int Med Res; 1996; 24(1):132-7. PubMed ID: 8674791
[TBL] [Abstract][Full Text] [Related]
10. The use of recombinant interferon alfa-2b in elderly patients with anti-HCV-positive chronic active hepatitis.
Bresci G; Del Corso L; Romanelli AM; Giuliano G; Pentimone F
J Am Geriatr Soc; 1993 Aug; 41(8):857-62. PubMed ID: 7688007
[TBL] [Abstract][Full Text] [Related]
11. Serum aminotransferase levels and histological disease in chronic hepatitis C.
Michielsen PP; Hauben EI; Ramon AM; Van Marck EA; Pelckmans PA
Acta Gastroenterol Belg; 1997; 60(1):11-4. PubMed ID: 9144972
[TBL] [Abstract][Full Text] [Related]
12. Polyunsaturated phosphatidyl-choline and interferon alpha for treatment of chronic hepatitis B and C: a multi-center, randomized, double-blind, placebo-controlled trial. Leich Study Group.
Niederau C; Strohmeyer G; Heintges T; Peter K; Göpfert E
Hepatogastroenterology; 1998; 45(21):797-804. PubMed ID: 9684137
[TBL] [Abstract][Full Text] [Related]
13. Randomised controlled trial of interferon alfa (lymphoblastoid interferon) in chronic non-A non-B hepatitis.
Jacyna MR; Brooks MG; Loke RH; Main J; Murray-Lyon IM; Thomas HC
BMJ; 1989 Jan; 298(6666):80-2. PubMed ID: 2493302
[TBL] [Abstract][Full Text] [Related]
14. Factors predictive of the response to interferon in patients with chronic hepatitis C.
Serfaty L; Giral P; Loria A; Andréani T; Legendre C; Poupon R
J Hepatol; 1994 Jul; 21(1):12-7. PubMed ID: 7963412
[TBL] [Abstract][Full Text] [Related]
15. [Recombinant interferon alfa in the treatment of chronic hepatitis C].
Coelho HS; Soares JA; Carvalho BB; Santos MA; Soldan M
Rev Assoc Med Bras (1992); 1995; 41(5):313-7. PubMed ID: 8731593
[TBL] [Abstract][Full Text] [Related]
16. Therapy of active chronic hepatitis with recombinant alpha 2b-interferon: an 18 month follow-up.
Bresci G; Parisi G; Banti S; Bertoni M
Eur J Med; 1993; 2(6):349-52. PubMed ID: 8252180
[TBL] [Abstract][Full Text] [Related]
17. Changes in serum hepatitis C virus RNA titer and response to interferon therapy in patients with chronic hepatitis C.
Aiyama T; Yoshioka K; Hirofuji H; Kusakabe A; Yamada M; Tanaka K; Kakumu S
Dig Dis Sci; 1994 Oct; 39(10):2244-9. PubMed ID: 7924750
[TBL] [Abstract][Full Text] [Related]
18. Treatment of posttransfusion non-A, non-B acute and chronic hepatitis with human fibroblast beta-interferon: a preliminary report.
Ohnishi K; Nomura F; Iida S
Am J Gastroenterol; 1989 Jun; 84(6):596-600. PubMed ID: 2499184
[TBL] [Abstract][Full Text] [Related]
19. Interferon for chronic hepatitis C in patients cured of malignancy.
Cesaro S; Rossetti F; De Moliner L; Crivellaro C; Zanesco L; Bortolotti F
Eur J Pediatr; 1994 Sep; 153(9):659-62. PubMed ID: 7957425
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of human leucocyte alpha-interferon treatment for chronic hepatitis C virus infection.
Weiland O; Chen M; Lindh G; Mattsson L; Schvarcz R; Sönnerborg A; Wahl M; Wejstål R; Widell A; Norkrans G
Scand J Infect Dis; 1995; 27(5):319-24. PubMed ID: 8588128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
